scispace - formally typeset
J

James Suh

Researcher at Foundation Medicine

Publications -  96
Citations -  10190

James Suh is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 29, co-authored 96 publications receiving 7405 citations. Previous affiliations of James Suh include Leidos & New York University.

Papers
More filters
Journal ArticleDOI

Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

Eric A. Collisson, +318 more
- 01 Jan 2014 - 
TL;DR: In this paper, the authors report molecular profiling of 230 resected lung adnocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses.
Journal ArticleDOI

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

TL;DR: Exome and genome sequences and whole-genome sequence analysis revealed frequent structural rearrangements, including in-frame exonic alterations within EGFR and SIK2 kinases, which are attractive targets for biological characterization and therapeutic targeting of lung adenocarcinoma.
Journal ArticleDOI

Pulmonary Pathologic Findings of Fatal 2009 Pandemic Influenza A/H1N1 Viral Infections

TL;DR: Preexisting obesity, cardiorespiratory diseases, and other comorbidities also were prominent findings among the decedents, similar to findings identified in past pandemics.
Journal ArticleDOI

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

David J. Clark, +224 more
- 31 Oct 2019 - 
TL;DR: A large-scale proteogenomic analysis of ccRCC is reported to discern the functional impact of genomic alterations and provides evidence for rational treatment selection stemming fromccRCC pathobiology.
Journal ArticleDOI

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Michael A. Gillette, +189 more
- 09 Jul 2020 - 
TL;DR: Comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK.